The effect of luteinizing hormone-releasing hormone antagonist in the progression prostate cancer with initial luteinizing hormone-releasing hormone agonist

The effect of luteinizing hormone-releasing hormone antagonist in the progression prostate cancer with initial luteinizing hormone-releasing hormone agonist - PC-antagonist

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009079

Enrollment

Registered

2012-11-01

Start date

2012-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

luteinizing hormone-releasing hormone agonist

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 25% elevation from PSA nadir and 2.0ng/ml Serum testosterone >20ng/dl WHO performance status 0 or 1 WBC over 3000/mm3 Pl t over 100,000/mm3 Hgb over 8.0g/mm3 Ccr over 50ml/m Bil less than 2.0mg/dl GOT(AST) less than 2.5xnormal range GPT(ALT) less than 2.5x normal range

Exclusion criteria

Exclusion criteria: Active infection Fever elevation >38 celsius Exclusion decided by physician

Design outcomes

Primary

Measure	Time frame
PSA response after three months with luteinizing hormone-releasing hormone agonist	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026